drugset / Trial / NCT00830648

Safety of a Second Dose of Biken's Varicella Vaccine

NCT00830648 ↗

Phase 4 Completed 122 enrolled Sanofi Pasteur, a Sanofi Company
NaSingle-groupOpen-labelPrevention

Summary

The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine. All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age. The expected total duration of follow-up (first visit to last visit) for each subject will be one month.

Timeline

Start
2009-01
Primary completion
2009-10
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Live Attenuated Varicella Virus Vaccine Vaccine 0.5 ml Subcutaneous

Indications